BioCentury
ARTICLE | Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

April 13, 2015 7:00 AM UTC

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax and Exviera dasabuvir with and without ribavirin for 12 weeks led to SVR4 rates of 97.1-98.8% vs. 82.9-85.3% for Incivek telaprevir plus peginterferon and ribavirin for 12 weeks followed by peginterferon and ribavirin alone for 12-36 weeks. In patients with HCV genotype 1a infection, Viekirax and Exviera plus ribavirin led to an SVR4 rate of 97.1% vs. 85.3% for Incivek plus peginterferon and ribavirin (p<=0.05). In patients with HCV genotype 1b infection, Viekirax and Exviera with and without ribavirin led to SVR4 rates of 98.8% and 97.6%, respectively, vs. 82.9% for Incivek plus peginterferon and ribavirin (p<=0.05 for both). In patients with HCV genotype 1a infection, Viekirax and Exviera plus ribavirin led to an SVR12 rate of 97.1%. In patients with HCV genotype 1b infection, Viekirax and Exviera with and without ribavirin led to SVR12 rates of 98.8% and 97.6%, respectively. Data, including SVR12 data for the Incivek arm, will be presented at the European Association for the Study of the Liver meeting in Vienna this month. ...